Regeneron to Acquire Core Assets of 23andMe for $256 Million in Bankruptcy Auction, Pledges to Preserve Consumer Genetics Mission and Strengthen Human Health Research In a major development within the…
BATURA Phase IIIb Trial Establishes Airsupra as a New Standard for As-Needed Asthma Rescue Treatment AstraZeneca has released the full results from its pivotal BATURA Phase IIIb trial, revealing that…
Daiichi Sankyo and Merck Launch Phase 3 IDeate-Esophageal01 Trial of Ifinatamab Deruxtecan in Advanced Esophageal Squamous Cell Carcinoma Daiichi Sankyo and Merck have officially initiated dosing in their pivotal Phase…
Cytokinetics Issues Equity Awards as Employment Inducements Under Nasdaq Rule 5635(c)(4), Advances Momentum in Cardiovascular Drug Development Cytokinetics, Incorporated (Nasdaq: CYTK), a leading biopharmaceutical company dedicated to developing novel therapies…
One World for Health: Inside the 78th World Health Assembly and the Future of Global Public Health From May 19 to 27, 2025, Geneva, Switzerland, will once again become the…
WHO and Universal Postal Union Launch Global Initiative to Expand Access to Eye Care Through Postal Networks In a groundbreaking move to address the global burden of vision impairment, the…
30 Years of Progress: Mobilizing the Health Sector to End Violence Against Women and Girls In the three decades since the landmark Beijing Platform for Action on Women was adopted…
BioMarin Bolsters Enzyme Therapy Portfolio with $270 Million Acquisition of Rare Disease Specialist Inozyme Pharma BioMarin Pharmaceutical, a leading biotech company focused on rare diseases and enzyme replacement therapies, announced…
Incyte’s Zynyz Secures First-Line Approval in Anal Cancer, Marking a Milestone for PD-1 Therapy in Rare Tumor Type In a significant development for the treatment of a rare and underserved…
Global Youth Scientists Shine at 75th Regeneron ISEF, Sharing Over $9 Million in Prizes In a celebration of youthful brilliance, scientific curiosity, and international collaboration, the 75th Annual Regeneron International…
European Commission Grants Approval to Bristol Myers Squibb’s Perioperative Opdivo Regimen for Resectable, High-Risk NSCLC with PD-L1 Expression ≥1% Bristol Myers Squibb has announced that the European Commission (EC) has…
Merck to Present Robust Set of Pulmonary Arterial Hypertension Data at ATS 2025, Underscoring Long-Term Commitment to Innovation and Patient Outcomes Merck , known as MSD outside the United States…